Trial Profile

A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) - A536-03

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luspatercept (Primary)
Indications Anaemia
Focus Therapeutic Use
Acronyms PACE-MDS
Sponsors Acceleron Pharma

Most Recent Events

23 Aug 2022 Results (n=108) reporting long-term safety and efficacy in patients with LR-MDS published in the Journal of Clinical Oncology
18 Oct 2018 Status changed from recruiting to completed.
17 Jun 2018 Results of the mutational and subgroup analyses of Lower-Risk Myelodysplastic Syndromes Patients Treated with Luspatercept (As of 8 Sept 2017; n=88), presented at the 23rd Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com